Closely held Nimbus Therapeutics is designing and developing precisely tailored small molecule medicines for challenging targets by leveraging a unique strategy that combines computational chemistry technologies with...

Closely held EsoBiotec is transforming cell therapy by engineering immune cells directly within a patient’s body, enabling the immune system to attack disease—potentially delivering cell therapy to patients in minutes...

Closely held Dotmatics is transforming the therapeutic research and development landscape with Luma, a groundbreaking solution in multimodal data management with the potential to address long-standing scientific...

Closely held JVP Labs is developing the only non-invasive, real-time cardiac filling pressure monitoring solution for managing congestive heart failure (CHF) patients—for both in the hospital and at home.

Closely held Longhorn Vaccines and Diagnostics is developing peptide vaccines and monoclonal antibodies aimed at preventing and reducing the global burden of medical conditions caused by key bacterial toxins, including...

Closely held Tasman Therapeutics is shifting the treatment landscape for treatment-resistant depression (TRD) with its registered, proprietary formulation—a first-of-its-kind, oral extended-release ketamine tablet.

Arch Biopartners (TXSV:ARCH; QTCQB:ACHFF) is at the forefront of developing breakthrough therapies to combat acute kidney injury (AKI) and prevent organ damage. By targeting the dipeptidase-1 (DPEP1) inflammation...

Closely held Future Fields is spearheading the world’s first synthetic biology system with an innovative transgenic bug-based approach—leveraging fruit flies to combine genetic engineering with insect farming to unlock...

Closely held Evergen, formerly RTI Surgical, is advancing innovative medical solutions across the cardiac, sports and orthopedics, plastic and reconstructive surgery, and neuro-spine clinical segments as the only...

Closely held MOBILion Systems is redefining analytical characterization through its next-generation separation science platform that is integrated with high-resolution mass spectrometry to achieve unprecedented...

Closely held VICO Therapeutics is developing antisense oligonucleotide (ASO) RNA modulating therapies for patients with severe genetic neurological diseases, including Huntington’s disease (HD) and spinocerebellar...